WELCOME TO ONCOVIRX

ABOUT US

OncoViRx is a discovery-stage, pharmaceutical start-up within the University of Pennsylvania’s UPstart program. In collaboration with the University’s Robertson and Winkler Laboratories, we are focused on discovering and developing novel small molecule therapies for the treatment of a range of hematologic malignancies (blood cancers). Specifically, we are working on compounds that inhibit the c-MYC, NF-KB, and Notch1 pathways, and anticipate initial clinical development will be in several sub-types of relapsed/refractory non-Hodgkin’s lymphoma and/or acute myeloid leukemia.

SMALL MOLECULEINHIBITORS

In collaboration with the University of Pennsylvania, OncoViRx is developing compounds that inhibit the c-MYC, NF-KB, and Notch pathways. Our goal is to develop novel treatments that are efficacious, have reduced short and long term side effect profiles, and are cost effective.